Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ABLYF NASDAQ:ASND NYSE:RDY NASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABLYFAblynx$50.63$50.63$12.50▼$55.04$3.81B1.995,063 shsN/AASNDAscendis Pharma A/S$194.62-0.5%$185.73$118.03▼$208.16$11.97B0.39403,501 shs224,675 shsRDYDr. Reddy's Laboratories$14.64-0.2%$14.32$12.26▼$16.19$12.24B0.32772,836 shs903,367 shsSMMTSummit Therapeutics$18.94$25.37$15.55▼$36.91$14.07B-1.024.57 million shs4.53 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABLYFAblynx0.00%0.00%0.00%0.00%0.00%ASNDAscendis Pharma A/S-0.49%-5.17%-1.87%+12.56%+63.24%RDYDr. Reddy's Laboratories-0.10%+2.59%+2.92%-3.89%-8.95%SMMTSummit Therapeutics0.00%-2.57%-29.04%-4.58%-40.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABLYFAblynx$50.63$50.63$12.50▼$55.04$3.81B1.995,063 shsN/AASNDAscendis Pharma A/S$194.62-0.5%$185.73$118.03▼$208.16$11.97B0.39403,501 shs224,675 shsRDYDr. Reddy's Laboratories$14.64-0.2%$14.32$12.26▼$16.19$12.24B0.32772,836 shs903,367 shsSMMTSummit Therapeutics$18.94$25.37$15.55▼$36.91$14.07B-1.024.57 million shs4.53 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABLYFAblynx0.00%0.00%0.00%0.00%0.00%ASNDAscendis Pharma A/S-0.49%-5.17%-1.87%+12.56%+63.24%RDYDr. Reddy's Laboratories-0.10%+2.59%+2.92%-3.89%-8.95%SMMTSummit Therapeutics0.00%-2.57%-29.04%-4.58%-40.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABLYFAblynx 0.00N/AN/AN/AASNDAscendis Pharma A/S 3.00Buy$244.3625.56% UpsideRDYDr. Reddy's Laboratories 2.80Moderate Buy$16.9515.82% UpsideSMMTSummit Therapeutics 2.65Moderate Buy$33.7978.38% UpsideCurrent Analyst Ratings BreakdownLatest ABLYF, SMMT, RDY, and ASND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025SMMTSummit TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight9/8/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.009/3/2025SMMTSummit TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.009/3/2025SMMTSummit TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.009/3/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$40.009/2/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$227.00 ➝ $230.009/2/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.008/27/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$44.00 ➝ $50.008/19/2025SMMTSummit TherapeuticsSummit RedstoneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$21.008/19/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$254.00 ➝ $260.008/19/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$40.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABLYFAblynx$62.73M60.74N/AN/A$2.71 per share18.68ASNDAscendis Pharma A/S$393.54M30.27N/AN/A($1.88) per share-103.52RDYDr. Reddy's Laboratories$3.81B3.21$1.03 per share14.20$4.73 per share3.09SMMTSummit Therapeutics$700K20,099.40N/AN/A$0.53 per share35.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABLYFAblynx-$122.67MN/A0.00∞N/AN/AN/AN/AN/AASNDAscendis Pharma A/S-$409.12M-$5.16N/A810.92N/A-54.94%N/A-24.31%11/13/2025 (Estimated)RDYDr. Reddy's Laboratories$663M$0.6622.1717.855.9216.99%17.25%11.63%11/4/2025 (Estimated)SMMTSummit Therapeutics-$221.32M-$1.01N/AN/AN/AN/A-208.64%-181.28%10/29/2025 (Estimated)Latest ABLYF, SMMT, RDY, and ASND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025SMMTSummit Therapeutics-$0.10-$0.76-$0.66-$0.76N/AN/A8/7/2025Q2 2025ASNDAscendis Pharma A/S-$1.42-$0.93+$0.49-$0.93$163.17 million$216.28 million7/23/2025Q1 25/26RDYDr. Reddy's Laboratories$0.18$0.20+$0.02$0.20$88.27 billion$988.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABLYFAblynxN/AN/AN/AN/AN/AASNDAscendis Pharma A/SN/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories$0.070.48%N/A10.61%N/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ALatest ABLYF, SMMT, RDY, and ASND DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/30/2025RDYDr. Reddy's Laboratoriesannual$0.09150.623832253665189%7/25/20257/10/20258/6/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABLYFAblynxN/AN/AN/AASNDAscendis Pharma A/SN/A1.020.69RDYDr. Reddy's Laboratories0.011.891.36SMMTSummit TherapeuticsN/A5.135.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABLYFAblynxN/AASNDAscendis Pharma A/SN/ARDYDr. Reddy's Laboratories3.85%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipABLYFAblynxN/AASNDAscendis Pharma A/S40.00%RDYDr. Reddy's Laboratories2.00%SMMTSummit Therapeutics84.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABLYFAblynxN/A75.25 millionN/ANot OptionableASNDAscendis Pharma A/S1,01761.21 million36.73 millionOptionableRDYDr. Reddy's Laboratories27,811834.92 million818.23 millionOptionableSMMTSummit Therapeutics110742.85 million112.17 millionOptionableABLYF, SMMT, RDY, and ASND HeadlinesRecent News About These CompaniesSummit Therapeutics (NASDAQ:SMMT) Shares Gap Up Following Insider Buying ActivitySeptember 14 at 10:14 AM | marketbeat.comSummit Therapeutics PLC (NASDAQ:SMMT) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 14 at 2:13 AM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) CEO Robert Duggan Acquires 333,394 SharesSeptember 13 at 8:34 PM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) CEO Mahkam Zanganeh Buys 333,394 SharesSeptember 13 at 8:34 PM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTSeptember 13 at 10:00 AM | prnewswire.comSiren L.L.C. Takes $13.41 Million Position in Summit Therapeutics PLC $SMMTSeptember 13 at 5:56 AM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Up After Insider Buying ActivitySeptember 13 at 2:15 AM | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.2% - Should You Sell?September 12, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) CEO Robert Duggan Purchases 5,000 SharesSeptember 12, 2025 | insidertrades.comSummit Therapeutics PLC (NASDAQ:SMMT) Receives Average Rating of "Moderate Buy" from AnalystsSeptember 12, 2025 | americanbankingnews.comSummit Therapeutics (SMMT) Is Down 21.0% After Mixed HARMONi Trial Data Raises Global Approval QuestionsSeptember 10, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTSeptember 10, 2025 | globenewswire.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down - Here's What HappenedSeptember 10, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Receives "Overweight" Rating from Cantor FitzgeraldSeptember 10, 2025 | marketbeat.comSummit Therapeutics' (SMMT) Buy Rating Reiterated at HC WainwrightSeptember 10, 2025 | marketbeat.comCORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law FirmSeptember 9, 2025 | globenewswire.comSummit Therapeutics Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 24, 2025 Deadline to file Lead Plaintiff Motion.September 9, 2025 | globenewswire.comSMMT Stock Plummets 25% on Regional Data Differences in NSCLC StudySeptember 9, 2025 | zacks.comPolar Asset Management Partners Inc. Trims Holdings in Summit Therapeutics PLC $SMMTSeptember 9, 2025 | marketbeat.com538,000 Shares in Summit Therapeutics PLC $SMMT Acquired by Adage Capital Partners GP L.L.C.September 9, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Given Overweight Rating at Cantor FitzgeraldSeptember 9, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABLYF, SMMT, RDY, and ASND Company DescriptionsAblynx OTCMKTS:ABLYF$50.63 0.00 (0.00%) As of 04/30/2019Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.Ascendis Pharma A/S NASDAQ:ASND$194.62 -0.96 (-0.49%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$194.50 -0.12 (-0.06%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Dr. Reddy's Laboratories NYSE:RDY$14.64 -0.03 (-0.17%) Closing price 09/15/2025 03:59 PM EasternExtended Trading$14.69 +0.05 (+0.38%) As of 09:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.Summit Therapeutics NASDAQ:SMMT$18.94 0.00 (0.00%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$18.84 -0.11 (-0.55%) As of 09:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
